WO2009011413A1 - エピトープタグ化c型肝炎ウイルス粒子の作製と利用 - Google Patents
エピトープタグ化c型肝炎ウイルス粒子の作製と利用 Download PDFInfo
- Publication number
- WO2009011413A1 WO2009011413A1 PCT/JP2008/062977 JP2008062977W WO2009011413A1 WO 2009011413 A1 WO2009011413 A1 WO 2009011413A1 JP 2008062977 W JP2008062977 W JP 2008062977W WO 2009011413 A1 WO2009011413 A1 WO 2009011413A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hcv
- sequence
- coding sequence
- protein coding
- virus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24251—Methods of production or purification of viral material
Definitions
- the present invention relates to epitopic tagged hepatitis C virus particles, vectors for producing the viruses, and cell lines producing the virus particles.
- the present invention also relates to a method for purifying the virus particle, a vaccine obtained by inactivating the virus particle, and an anti-hepatitis C virus antibody against the virus particle as an antigen.
- HCV Hepatitis C virus
- Non-patent Document 1 Hepatitis C virus
- hepatitis C is a serious infection with a poor prognosis, and about half of the patients with chronic hepatitis C will surely worsen the disease state to cirrhosis and liver cancer. For these reasons, it is desirable to develop antiviral drugs and vaccines aimed at preventing the occurrence of carriers and eliminating viruses.
- a simple and highly purified method for purifying proteins obtained in a cell culture system is to express the target protein as a fusion protein with the labeling protein, and specifically bind to the antibody against the target protein and this.
- Techniques for purifying fusion proteins with molecules that can be known are known.
- Epitope tags include: FLAG peptide, 3XFLAG peptide, HA peptide, 3XHA peptide, fflyc peptide, 6XH is peptide, GST polypeptide, MBP polypeptide, PDZ domain polypeptide, TAP (Tandem Affinity Purification ) Peptides, alcalifosphatase, avidin, etc. are known. These peptides or polypeptides are usually fused to the N-terminus or C-terminus of the protein of interest, but in some cases can also be inserted into the protein of interest.
- the genome of HCV is a (+) single-stranded RNA consisting of about 9600 nucleotides.
- This genomic RNA consists of a 5 'untranslated region (also referred to as 5' NTR or 5 'UTR), a translated region composed of a structural region and a non-structural region, and a 3' untranslated region (3 'NTR or 3''(Also referred to as UTR).
- the structural region encodes HCV structural protein
- the nonstructural region encodes multiple nonstructural proteins.
- HCV structural proteins Core, El, E 2 and p7
- nonstructural proteins NS2, NS3, NS4A, NS4B , NS5A, and NS5B
- Core is the core protein
- E1 and E2 are envelope proteins.
- Nonstructural proteins are responsible for the replication of the virus itself.
- S2 has meta-protease activity
- NS3 has serine protease activity (1/3 on the N-terminal side) and helicase activity (2/3 on the C-terminal side).
- NS4A is a cofactor for NS3 protease activity
- NS5B has been reported to have RNA-dependent RNA polymerase activity.
- HCV is wrapped in a film called an envelope.
- the envelope consists of components derived from the membrane of the host cell and proteins derived from the virus.
- the protein constituting the envelope of HCV consists of envelope protein 1 (referred to as E1), envelope protein 2 2) and p7.
- E1 and E2 have a transmembrane region at the C-terminus, and are anchored in the HCV membrane via this transmembrane region, and are involved in HCV particle formation and infection (Non-patent Document 4, Non-patent Document 4) Reference 5).
- HVR1 hypervariable region 1
- HVR2 hypervariable region 2
- HVR1 consists of 27 amino acids in the amino terminal portion of the E2 protein, and is exposed on the surface of the E2 protein to form a B cell epitope.
- the diversity of the amino acid sequence of HVR1 shows up to 80%, but there are several places where amino acids are conserved, so it is thought that a certain secondary structure is necessary for the survival of the virus. Yes.
- HVR1 has almost no cysteine residue-asparagin-linked chain addition signal.
- HRV2 consists of 7 amino acids and is located at positions 91-97 from the amino terminus of the E2 protein. HRV2 is present in the HCV lb genome, but not in other genotypes of HCV.
- Non-Patent Document 2 As an example of an epitope tag inserted into a viral particle in HCV, the E2 protein HVR1 of the JFH-1 strain (HCV2a type) is known to be substituted with the HA peptide, which has been confirmed to be infectious. (Non-Patent Document 2). However, there is no report that this infectious epitope-tagged HCV particle could be purified with high purity.
- Patent Document 1 W005080575A1
- Patent Document 2 W006022422A1
- Non-Patent Document 1 Choo, QL. Et al., Science, 244: 359-362, 1989
- Non-Patent Document 2 Wakita, T. et al., Nat. Med., 11: 791-796, 2005 Non-Patent Document 3 Zahn, A. & Allainl, JP., J. Gen. Virol., 86: 677-685, 2005 Non-Patent Document 4 Voisset, C. & Dubuisson, Biology of the Cell, 96: 413-420,
- Non-patent literature 5 Op De Beeck, A. et al ,, J. Gen. Virol., 82: 2589-2595, 2001
- Non-patent literature 6 Hi jikata, M. et al., Biochem Biophys Res Comraun., 175: 220 -228, 1991 DISCLOSURE OF THE INVENTION
- An object of the present invention is to provide an epitope-labeled HC V particle capable of easily and highly purifying HCV particles, a purification method thereof, a vaccine using the high purity HCV particles, and the like. It is in.
- the inventors of the present invention have studied the types of epitope tags that do not affect the productivity and infectivity of HCV particles in cell culture, and combinations of HCV proteins to which the epitope tag is added and the addition position. Epitope-tagged HCV particles were successfully produced. Furthermore, a clone that produces this HCV particle at high production was prepared, and it was confirmed that the produced epitope-tagged HCV particle could be purified to high purity in one step using an anti-epitope tag antibody column, and the present invention was completed. It was.
- the present invention relates to the following (1) to (15).
- a nucleic acid comprising the following (a), (b) or (c), wherein the epitope tag peptide is inserted into the hypervariable region 1 (HVR1) of the E2 protein coding sequence of (a), (b) or (c).
- HVR1 hypervariable region 1
- HCV J6CF strain 5 untranslated region, Core protein coding sequence, E1 protein coding sequence, E2 protein coding sequence and p7 protein coding sequence, NS2 of JFH-1 strain Chimeric HCV genome comprising coding sequence, NS3 protein coding sequence, NS4 A protein coding sequence, NS4B protein coding sequence, NS5A protein coding sequence, NS5B protein coding sequence 3 'untranslated region
- the above linker sequence is a GGG sequence, GGGGS sequence or (GGGGS) 3 sequence, or a part of the GGG sequence, GGGGS sequence or (GGGGS) 3 sequence, which lacks 1 to 10 amino acids.
- nucleic acid according to any one of the above (1) to (4) represented by SEQ ID NO: 1, 1, 2, 30, 3 1, 4 1 or 42 (however, if the nucleic acid is RNA, The base symbol “TJ” shall be read as “UJ”.
- nucleic acid described in (6) above which is represented by SEQ ID NO: 20 or 21 (when the nucleic acid is RNA, the base symbol “T” in the sequence listing shall be read as “U”).
- a vector comprising the nucleic acid according to any one of (1) to (7) above.
- the above release step consists of an epitope tag peptide-containing buffer, calcium-free buffer, pH 2.5 to pH 4.0, 0.1 M glycine buffer, pH 4.0 to pH 5.0, 1 M arginine hydrochloride.
- Figure 1 shows the structure of HCV E2. N1 to N11 are glycosylation sites, HVR is Hyper Variable Region, and TMD is Trans Membrane Domain. A part of the amino acid of J6 / JFH-1 E2 HVR1 (underlined) was removed, and a FLAG tag sequence (underlined) was inserted there.
- Figures 2A, 2B and 2C show the construction of PJ6 / JFH-1 (1XFLAG) and pJ6 / JFH-1 (3XFLAG) plasmids.
- Figure 2B is a continuation of Figure 2A
- Figure 2C is a continuation of Figure 2B.
- Figure 3 shows the change in the amount of HCV Core protein in the culture supernatant after introducing T6 / JFH-1 RNA and J6 / JFH-1 (3XFLAG) RNA into Huh-7 cells.
- J6 / JFH-1 produced no change, but J6 / JFH-1 (3XFLAG) decreased Core production until day 22, but then increased and increased on day 35. And almost the same production amount.
- Figure 4 shows that after introducing J6 / JFH-1 RNA and J6 / JFH-1 (3XFLAG) RNA into Huh-7 cells,
- Figure 5 shows the behavior of HCVE2 protein treated with endoglycosidase (PNGase F) at 4, 17, 30, and 43 days after introducing J6 / JFH-1 (3XFLAG) RNA into Huh-7 cells.
- PNGase F endoglycosidase
- Figure 6 shows the sequence analysis of the HCV genome on the 8th and 39th day after introduction of J6 / JFH-1 (3XFLAG) RNA.
- wasparagine (N6) the glycosylation site in the E2 region, was replaced with lysine (K).
- FIG. 7 shows the amount of HCV Core protein in the purified solution of J6 / JFH-1 (3XFLAG) virus.
- HCV Core protein was detected by elution of 1XFLAG peptide or 3XFLAG peptide, confirming the purification of HCV particles.
- Figure 8 shows the contaminating proteins contained in the purified J6 / JFH-1 (3XFLAG) virus solution.
- the purified virus solution contained almost no contaminating protein.
- Figure 9 shows the infectivity of purified J6 / JFH-1 (3XFLAG) virus.
- the intracellular HCV RNA was quantified on the 4th day after infection with each virus.
- the purified virus was confirmed to have the same infectivity as the unpurified virus.
- FIG. 10A, FIG. 10B and FIG. 10C show the construction diagrams of PJ6 / JFH-1 (1XFLAG) N ⁇ K and pJ6 / JFH-1 (3XFLAG) N ⁇ K plasmid.
- FIG. 10 08 is a continuation of FIG. 1 O A
- FIG. 10 C is a continuation of FIG. 10 B.
- FIG 11 shows the structural diagram of HCV E2.
- N1 to N11 are glycosylation sites
- HVR is Hyper Variable Region
- TMD is Trans Membrane Domain.
- a portion of the amino acid (underlined) of E2 HVRl of JFH-1 was removed, and a FLAG tag sequence (underlined) was inserted there.
- Fig. 12 A, Fig. 12 B and Fig. 12. C show the construction of pJFH-1 (1 XFLAG) and pJFH-1 (3XFLAG) plasmids.
- Figure 12B is a continuation of Figure 12A
- Figure 12C is a continuation of Figure 12B.
- Figure 13 shows the structural diagram of HCV E2.
- N1 to N11 are glycosylation sites
- HVR is Hyper Variable Region
- TMD is Trans Membrane Domain.
- pTH / JFH-1 E2 HVRl A part of the amino acid (underlined) was removed, and a FLAG tag sequence (underlined) was inserted there.
- Fig. 14 A, Fig. 14 B and Fig. 14 C show construction diagrams of pTH / JFH-1 (1XFLAG) and pTH / JFH-1 (3XF LAG) plasmids.
- Figure 14B is a continuation of Figure 14A
- Figure 14C is a continuation of Figure 14B.
- Epitope-tagged HCV particle means an HCV particle in which an epitope tag peptide is added to the structural protein of HCV.
- the epitopylated HCV particles can be produced in a cell culture system and preferably possess infectivity.
- one form of gene that can generate HCV particles is the viral genomic RNA of the JFH-1 strain, in order from 5 to 3 ', 5' untranslated region, Core protein coding sequence, E1 protein Coding sequence, E2 protein coding sequence, p7 protein coding sequence, NS2 protein coding sequence, NS3 protein coding sequence, NS4A protein coding sequence, NS4B protein coding sequence, NS5A protein coding sequence, NS5B protein coding sequence and 3 'untranslated It is RNA consisting of regions.
- Another form of gene that can generate HCV particles is a chimeric gene consisting of two or more types of viral genomic RNA of HCV strains. 5 'untranslated region, Core protein coding sequence, E1 protein coding sequence, E2 protein coding sequence, p7 protein coding sequence and NS2 protein coding sequence of HCV strains other than Hl strain, and NS3 protein core of JFH-1 strain NS4A protein coding sequence IJ, NS4B protein coding sequence, NS5A protein coding sequence, NS5B protein coding sequence RNA consisting of 3 'untranslated region.
- the genes capable of generating HCV particles include the following nucleic acids (a), (b) and (c), that is,
- Chimeric HCV genome containing NS5A protein coding sequence, NS5B protein coding sequence and 3 'untranslated region preferably from the 5' side to the 3 'side, preferably from the JFH-1 strain
- E2 protein coding sequence, p7 protein coding sequence, and NS2 protein coding region coding sequence up to N-terminal 33 amino acid residues, and JFH-1 strain NS2 protein coding region N-terminal 34 amino acid residues to C-terminal The sequence to encode,
- the above HCV genome encodes EDKDDDDKGGG (SEQ ID NO: 4 9) or DYKDHDGDYKDHDIDYKDDDDKGGG (SEQ ID NO: 50), which is an epitopic tag peptide in the hypervariable region 1 (HVR1) of the E2 protein coding sequence.
- the nucleic acid sequence to be inserted is inserted in-frame, or a part of the region is replaced with the above-mentioned epitope tag peptide to produce the epitope-tagged HCV genomic DNA. Then, using this DNA, “epitope-tagged HCV particles” are produced in a cultured cell system to obtain high-purity purified epitope-tagged HCV particles.
- HCV genomic DNA having an epotope tag in the HCV structural protein “Epitope tag” is particularly suitable if it can be used for HCV labeling.
- epipe tag also called flag peptide, Flag peptide
- 3XFLAG peptide also called 3xFLAG peptide, 3xFlag peptide, 3Xflag peptide
- MBP polypeptide MBP polypeptide, PDZ domain polypeptide, TAP (Tandem Affinity Purificat ion) peptide, Al force phosphatase, avidin and the like.
- a FLAG peptide amino acid sequence: DYKDDDDK (SEQ ID NO: 51)
- 3XFLAFG peptide amino acid sequence: DYKD HDGDYKDHDIDYKDDDDK (SEQ ID NO: 52)
- the 3XFLAG peptide is more preferred.
- the place where the above epitope tag is added is the HVR1 region of the E2 protein of the HCV particle.
- the epitope tag is inserted in-frame between the 8th and 19th amino acids from the N-terminus of the E2 protein with low homology between each HCV strain in the HVR1 region (so that the reading frame does not shift), or Alternatively, it is more preferable to remove the 11th to 1st amino acids at the N-terminal and insert an epitopic tag peptide here. Add an appropriate linker to the C-terminus of the above epitope tag as necessary.
- an amino acid sequence GGG (SEQ ID NO: 53), GGGGS (SEQ ID NO: 54), or (GGGGS) X3 (also referred to as (GGGGS) 3 ), or a part of these amino acid sequences, 1 to 1 Peptides containing about 0, preferably 1 to 5, more preferably 1 to 2 amino acid deletions, substitutions or additions are used, and preferred examples include GGG, GGG GS (SEQ ID NO: 5 4), (GGGGS) X 3 is mentioned, but GGG is more preferable.
- the method of introducing a nucleic acid encoding the above-mentioned epitope tag into the HCV genome is the PCR product obtained by performing a polymerase chain reaction (PCR) using a synthetic primer containing the nucleotide sequence encoding the epitope tag with the cDNA of the HCV genome in a vertical shape.
- PCR polymerase chain reaction
- a method of recombining to cDNA of HCV genome by enzyme treatment or ligation treatment can be mentioned. Examples of these techniques are shown in the examples below.
- the HCV strain to be used is not limited. Genotype la (eg, H77 strain (GenBank accession number AF011751)) classified by phylogenetic analysis using the base sequence of HCV strain, genotype lb (eg J1 strain (GenBank accession number D8 9 81
- Conl strain (GenBank accession number AJ238799, Con-1 strain, sometimes referred to as conl strain), TH strain (Wakita, T. et al., J. Biol. Chem., 269, 14205-14210) ,
- genotype 2a eg, JFH-1 strain (GenBank accession number AB047639, sometimes referred to as Ji3 ⁇ 4l strain), J6CF strain (GenBank accession number AF177036), JCH-1 (GenBank Session number AB047640), JCH-2 (GenBank accession number AB047641), JCH-3 (GenBank accession number AB04764) 2), JCH- (GenBank accession number AB047643), JCH-5 (GenBank accession number AB047644), JCH-6 (GenBank accession number AB047645)), genotype 2b (eg HC-J8 strain (GenBank Accession number D01221)), genotype 3a (eg NZL1 strain (GenBank accession number D17763)), genotype 3b (eg Tr-Kj (GenBank accession number D49374)) Can be used.
- JFH-1 strain GenBank accession number AB047639, sometimes referred to as Ji3 ⁇ 4l strain
- J6CF strain
- the nonstructural protein coding sequence and the 3 ′ untranslated region are derived from the JFH-1 strain, and the 5 ′ untranslated region and the structural protein code Nucleic acid sequences derived from TH1, JFH-1 or J6CF strains were used.
- PCR is carried out using a vector obtained by cloning the cDNA of HCV genomic RNA as a cage and using synthetic DNA encoding the epitope tag peptide as a primer.
- cDNA encoding an envelope protein having an epitope tag added / inserted at the target location can be obtained.
- a cDNA fragment encoding an envelope protein with an epitope tag was isolated by digestion with an appropriate restriction enzyme, and a full-length HCV genomic RNA cDNA was cloned downstream of a promoter such as the T7 promoter.
- a full-length HCV cDNA having an epitope tag can be obtained by inserting a cDNA fragment encoding an envelope protein having an epitope tag sequence isolated at the same position after digestion with the same restriction enzyme as described above.
- the full-length HCV genomic RNA cDNA vector used here is capable of producing HCV particles when RNA transcribed from this vector is introduced into HCV-permissive cells such as Huh7 cells. Details of structure and fabrication are described in W004104198A1, W006 022422A1, Wakita, T. et al ,, Nat. Med. 11: 79 ⁇ 796, 2005, Lindenbach, BD. Et al., Science 309: 623-626, 2005 ing.
- RNA from HCV cDNA By synthesizing RNA from HCV cDNA with an epitope tag coding sequence under the control of a promoter and introducing this RNA into cells, cells containing epitope-tagged HCV particles can be obtained.
- Epitope-tagged HCV particles Can.
- the promoter includes, but is not limited to, a force T7 promoter including T7 promoter, SP6 promoter, and T3 promoter.
- Kits such as the MEGAscript T7 kit (Ambion) can be used to introduce HCV cDNA under the control of the T7 promoter and to prepare RNA in vitro using the cloned nucleic acid as a cage. .
- the cells into which RNA is introduced may be cells that allow HCV particle formation, such as Huh7 cells, HepG2 cells, IMY-N9 cells, HeLa cells, 293 cells, or Huh7 cells, HepG2 cells, IMY-N9 cells, HeLa Examples thereof include cells or cells obtained by expressing CD81 gene and / or Claudinl gene in 293 cells. Of these, Huh7 cells or Huh7 cell derivatives are preferably used. Derivatives of Huh7 cells include Huh7.5 cells and Huh7.5.1 cells.
- Examples of methods for introducing RNA into cells include calcium phosphate coprecipitation method, DEAE dextran method, ribofusion method, microinjection method, and electroporation method, but lipofection method and electroporation method are preferred. The method is more preferred.
- cDNA may be introduced into the cell, and in this case, the HCV cDNA with the epitope tag code sequence added to the RNA polymerase I promoter and terminator vector (Neumann, G. et. al., Virology, 202: 477-479, 1994, W02 007 / 037428A1), and inserted into cells in the same manner as RNA and expressed.
- the ability of a cell to produce virus particles can be evaluated using, for example, an antibody against Core protein, E1 protein, or E2 protein that constitutes HCV virus particles released into the culture medium. It is also possible to indirectly evaluate the ability to produce HCV viral particles by amplifying and detecting HCV genomic RNA contained in HCV viral particles in the culture medium by RT-PCR using specific primers. it can. Whether the produced virus has infectivity or not can be determined by treating HCV-permissive cells (eg Huh7) with the supernatant obtained by culturing cells into which HCV RNA has been introduced. Ability to count the number of infected cells by immunostaining the above cells with anti-core antibody ⁇ above The cell extract can be electrophoresed on SDS-polyacrylamide gel and evaluated by detecting the core protein by Western blot.
- HCV-permissive cells eg Huh7
- a cell line that continuously produces HCV particles can be obtained by subculturing cells into which the HCV genomic RNA prepared in (2) above has been introduced. Continuing the culture in this way may cause a compatible mutation in the HCV genome and significantly improve HCV particle production.
- nucleic acids (a) to (c) above when the first amino acid following the last sequence of HVR1 (Puntoriero, G. et al., EMB0 J. 17: 3521-3533, 1998) 1 A mutation in which asparagine, which is the 22nd or 124th amino acid, is substituted with lysine is suitable as a mutation in producing an epitope-tagged HCV particle.
- the nucleic acid (a) or (b) it is more preferable to mutate so that the 124th amino acid is substituted from asparagine to lysine.
- the 122nd amino acid is changed from asparagine to lysine.
- the adaptive mutation in the present invention can be obtained by subculture as described above, but can also be artificially introduced.
- a mutation-introducing primer is designed and PCR is carried out to synthesize DNA with the mutation introduced.
- mutants may be prepared using Quick Charge II XL Site-Directed Mutagenes kit (Stratagene), which is commercially available as a mutant preparation kit.
- a carrier to which a protein capable of binding to the epitope tag is bound is used.
- the most common protein is an antibody against an epitope tag peptide.
- a suitable epitope tag is a FLAG peptide or 3XFLAG peptide, and an anti-FLAG antibody that can bind to these peptides, such as a carrier to which M2 antibody or M5 antibody is bound (immobilized) ( Any of them can be obtained from Sigma).
- HCV H2.5 to pH4.0
- 1M Argyyun HCl buffer pH4.0 to pH5.0
- ImM ⁇ ; Lm M hydrochloric acid can be used.
- P H6. 0 ⁇ P H8. 0 near neutral pH of buffer after elution
- the purified HCV particles can be electrophoresed on SDS-polyacrylamide gel, and the HCV particles can be determined by detecting the HCV-derived protein by Western blot.
- the high purity epitope-tagged HCV particles are suitable for use as a vaccine and as an antigen for the production of anti-HCV antibodies.
- the prepared epitope-tagged HCV particles can be inactivated by methods known in the art.
- Virus inactivation is formalin, ⁇ -op It can be achieved by adding an inactivating agent such as oral piolactone and dartardial aldehyde to the virus suspension and reacting with the virus (Appa iahgari et al., Vaccine, 22: 3669-3675). , 2004).
- the infectivity of the virus can be lost and it can be quickly inactivated.
- Ultraviolet irradiation has little effect on the proteins that make up the virus and can inactivate the virus.
- the ultraviolet ray source for inactivation can be performed using a commercially available germicidal lamp, in particular, a 15 W germicidal lamp, but is not limited thereto.
- HCV particles purified by the method described above are used, but the inactivation method is not limited by the state of purification / unpurification.
- the epitope-tagged HCV particles can be inactivated by irradiating a solution containing the epitope-tagged HCV particles with 20 mW / cm 2 of ultraviolet light at room temperature for 5 minutes or more.
- the actin of the present invention contains 10% to 95%, preferably 25% to 70%, of an active ingredient (virus particle or a part thereof) in the form of either a solution or a suspension, and can be administered.
- an active ingredient virus particle or a part thereof
- Prepared It can be prepared in the form of a solid suitable for dissolution or suspension in a liquid.
- the preparation may be emulsified or encapsulated in ribosomes.
- Active immunogenic ingredients such as HCV particles are pharmaceutically acceptable and are often mixed with excipients compatible with the active ingredient.
- Suitable excipients include, for example, water, saline, dextrose, glycerol, ethanol, and the like, and mixtures thereof.
- the vaccine may contain minor amounts of adjuvants (eg, humidifiers or emulsifiers), pH buffers, and / or adjuvants that enhance the efficacy of the vaccine.
- adjuvants examples include, but are not limited to, for example, aluminum hydroxide, N-acetylmyl lamil L-treo-luo D—soglutamine (thr-MDP), N-acetyl-nor-muramyl L Alani Lou D—Isoglutamine (referred to as CGP 1 1 6 3 7, nor I MD P),
- RIBI 2- (1, 1-2, dipanoremy toinole sn-glycero 3-hydroxyphosphoryloxy) ethylamine (referred to as CGP 1 98 3 5A, MTP-PE), And RIBI.
- RIBI consists of 3 components extracted from bacteria, namely monophosphoryl lipid A, trehalose dimycolate, and cell wall skeleton (HPL + TD M + CWS) in 2% squalene / T ween® 80 in emulsion Is contained.
- the efficacy of an adjuvant can be determined by measuring the amount of antibody produced by administering a vaccine composed of HCV particles.
- the vaccines of the invention are usually administered parenterally, for example by injection, such as subcutaneous or intramuscular injection.
- Other formulations suitable for other modes of administration include suppositories, and in some cases oral formulations.
- Adjuvants are nonspecific stimulators of the immune system. They enhance the host's immune response to the HCV vaccine. Specific examples of adjuvants known in the art include Freund's complete and incomplete adjuvants, vitamin E, nonionic block polymers, muramyl dipeptides, saponins, mineral oils, vegetable oils and Carbopol. Adjuvants that are particularly suitable for mucosal applications include, for example, E. coli heat-labile toxin (LT) or cholera toxin (CT).
- LT heat-labile toxin
- CT cholera toxin
- the vaccine of the present invention includes an adjuvant.
- a pharmaceutically acceptable carrier or diluent include a stabilizer, a carbohydrate, (for example, administration with sorbitol, mannitol, starch, sucrose, glucose, dextran, proteins such as albumin or casein, protein-containing substances such as sushi serum or skim milk, and puffer (eg, phosphate buffer) can do.
- the vaccine of the present invention is administered in a manner suitable for the dosage form and in such an amount as to have a prophylactic and / or therapeutic effect.
- the amount to be administered is usually the antigen per dose
- route of administration such as oral, subcutaneous, intradermal, intramuscular and intravenous routes.
- the vaccines of the present invention may be given on a single dose schedule or preferably on a multiple dose schedule.
- a combined dosing schedule 1 to 10 individual doses are given at the beginning of the inoculation, followed by the time interval required to maintain and / or strengthen the immune response, for example 1 to 2 as the second dose.
- Another dose can be given after 4 months. If necessary, administration can be continued after several months.
- the dosage regimen will also be determined, at least in part, by the individual's needs and will depend on the judgment of the physician.
- the vaccine of the present invention may be administered together with other immunoregulatory agents (for example, immunoglobulins).
- immunoregulatory agents for example, immunoglobulins.
- the vaccine of the present invention may be administered to a healthy person to induce an immune response against HCV in the healthy person, and used prophylactically against a new HCV infection. Furthermore, it may be used as a therapeutic vaccine to eliminate HCV by administering it to a patient infected with HCV and inducing a strong immune response against HCV in vivo.
- the epitope-tagged HCV particles of the present invention are useful as antigens for antibody production because they can be easily purified and have high purity.
- the animal serum contains antibodies against impurities, if impurities exist in the HCV particle sample used for animal immunity, the serum is purified using an HCV antigen column to remove antibodies against these impurities. There is a need. However, since the epitope-tagged HCV particles of the present invention can be obtained as high-purity HCV, such a purification step is unnecessary.
- An anti-HCV antibody can be produced by administering the epotope-tagged HCV particle of the present invention to a mammal or a bird.
- mammals include mice, rats, rabbits, goats, hidges, horses, horses, monoremots, pigeons, Bactrian camels, and llamas. Giant camel, Bactrian camel and llama
- an antibody consisting of only an H chain.
- avian animals include eagle birds, geese, and ostriches. Animals administered the particles of the present invention
- the antibody can be obtained according to a known method.
- a hybridoma that produces monoclonal antibody-producing cells can be produced using cells of an animal immunized with the epotope-tagged HCV particles of the present invention.
- a method for producing a hyperidoma is well known, and a method described in Antibodies: A Laboratory Manual (Cold Spring Harbor Laboratory, 1988) can be used.
- Monoclonal antibody-producing cells may be produced by cell fusion, or may be produced by other methods such as immortalization of B lymphocytes by introduction of oncogene DNA or infection with Epstein-Barr virus.
- Monoclonal antibodies and polyclonal antibodies obtained by these methods are useful for the diagnosis, treatment and prevention of HCV.
- the antibody produced using the epotope-tagged HCV particles of the present invention is used for the treatment and prevention of hepatitis C. It is also used to prevent HCV infection from donor organs by organ transplantation. Furthermore, the above antibody can be used in combination with existing antiviral agents such as interferon and rivapirin.
- the effective dose of the anti-HCV antibody is selected in the range of 0.O O l mg to 100 mg per kg body weight. Alternatively, a dose of 0.01 to: 1 00 0 0 0 0 mg Z b ody per patient can be selected. However, therapeutic agents containing anti-HCV antibodies produced using the epitope-tagged HCV particles of the present invention are not limited to these doses.
- the administration route of the therapeutic agent is not particularly limited, but is preferably subcutaneous, intradermal, or intramuscular, and more preferably intravenous.
- the timing of administration of the therapeutic agent may be before or after the clinical symptoms of the disease occur.
- a therapeutic agent containing an anti-HCV antibody produced using the epotope-tagged HCV particles of the present invention as an active ingredient can be formulated according to a conventional method (Remington's Pnarmaceutical Science, Latest Edition, Mark Pub ⁇ i). sning Company, Easton, USA) and may contain both pharmaceutically acceptable carriers and additives.
- Such carriers and pharmaceutical additives include water, pharmaceutically acceptable organic solvents, collagen, polyvinyl alcohol, polyvinyl pyrrolidone, carboxy vinyl polymer, sodium carboxymethyl cellulose, sodium polyacrylate Lithium, sodium alginate, water-soluble dextran, sodium carboxymethyl starch, pectin, methylcellulose, ethinolecellulose, xanthan gum, gum arabic, casein, agar, polyethylene glycol, diglycerin, glycerin, propylene glycol, petrolatum, paraffin, Examples include stearyl alcohol, stearic acid, human serum albumin (HSA), mannitol, sorbitol, lactose, and surfactants acceptable as pharmaceutical additives.
- HSA human serum albumin
- the actual additive is selected, for example, from the above alone or in appropriate combination depending on the dosage form of the therapeutic agent of the present invention, but is not limited thereto.
- the anti-HCV antibody prepared using purified epotope-tagged HCV particles is dissolved in a solvent such as physiological saline, buffer solution, grape grape solution, etc.
- Agents such as Tween 80, Tween 20, gelatin, human serum albumin and the like can be used.
- it may be lyophilized to obtain a dosage form that is dissolved and reconstituted before use.
- sugar alcohols or saccharides such as mannitol and glucose are used. be able to.
- Example 1 Construction of J6 / JFH-1 plasmid with FLAG tag sequence inserted into HCV E2 HVR1 region
- the HCV genomic RM cDNA is a J6CF strain from 5 'UTR to NS2 N-terminal 16 amino acid residues of genotype 2a (GenBank accession number AF177036, Yanagi, M. et al., Virology, 262 (1999) p250 -263) 3 from the N-terminal 17 amino acid residues of NS2.
- Up to UTR is also the JFH-1 strain (genbank accession number AB0476) of genotype 2a
- H-1 chimeric cMA was used.
- a FLAG tag to be inserted a cDNA in which the FLAG sequence was repeated once or three times was inserted.
- Each of these prepared plasmids is p
- pJFHl (Wakita, T. et al. Nat. Med., A plasmid DNA constructed by cloning cDNA corresponding to the entire region of genomic RNA derived from JFH1 strain into pUC19 plasmid. 11 (2005) p791-796 (International Publication W02004 / 104198) was digested with EcoRI and then partially digested with Bell to remove the plasmid from the EcoRI site to the first Bell site (approximately 2840 bp). The fragment was purified.
- a genomic cDNA derived from the J6CF strain cloned in pUC19 plasmid, pJ6CF (GenBank accession number AF177036, Yanagi, M., et al., Virology 262: 250-263, 1999) is partially composed of EcoRI and Bell. The approximately 2840 bp fragment obtained by digestion was ligated to the above fragment to obtain J6 / JFH1.
- the J6 / JFH1 cDNA was used as a saddle, and 10 1 buffer 10 1 and 2 mM dNTP mixture 4 1 and 10 ⁇ were attached to the Phusion High-Fidelity DNA Polymerase kit (FINNZYMES).
- Primers E2-F (SEQ ID NO: 4) and IF-R (SEQ ID NO: 5) were each added at 1 ⁇ l, and finally deionized water was added to make the total amount 49.5 ⁇ l. Thereafter, Phusion DNA Polymerase (FINNZYMES) was added 0.5 ⁇ l and PCR reaction was performed.
- the PCR reaction was performed under conditions of 30 cycles, with one cycle consisting of 98 ° C for 10 seconds, 55 ° C for 15 seconds, and 72 ° C for 30 seconds.
- the obtained PCR product was designated as PCR product no.
- 10 X buffer solution (10 ⁇ 1, 2 mM dNTP mixture solution, 4 ⁇ 1, 10) attached to the Phusion High-Fidelity DNA Polymerase kit (FI ⁇ ZYMES) was used. 1 ⁇ l each of / 2-R (SEQ ID NO: 6) and IF-F (SEQ ID NO: 7) was added, and finally deionized water was added to make the total amount to 49.51. afterwards
- PCR reaction was performed.
- the PCR reaction was performed under conditions of 30 cycles, with one cycle consisting of 98 ° C for 10 seconds, 55 ° C for 15 seconds, 72 ° C for 1 minute 30 seconds.
- the obtained PCR product is designated as PCR product no. 2. It was.
- the 10X buffer solution (10 ⁇ 1) and the 2mM dNTP mixture solution (4 ⁇ l, 10 ⁇ m) attached to the Phusion High-Fidelity DNA Polymerase kit (FINNZYMES) ⁇ 2- F (SEQ ID NO: 4) and 3F-R (SEQ ID NO: 8) were each added in ljul, and finally deionized water was added to make the total amount 49.5 ⁇ 1. Thereafter, 0.5 1 of husion DNA Polymerase (FI ⁇ ZYMES) was added and PCR was performed. The PCR reaction was performed under the conditions of 30 cycles, with one cycle consisting of 98 ° C for 10 seconds, 55 ° C for 15 seconds, and 72 ° C for 30 seconds. The obtained PCR product was designated as PCR product no.
- FI ⁇ ZYMES husion DNA Polymerase
- the J6 / JFH1 cDNA was used as a cage, and the 10X buffer solution (10 ⁇ 1, 2mM dNTP mixture solution 4/1, 10M) attached to the Phusion High-Fidelity DNA Polymerase kit (FI ⁇ ZYMES) was used.
- E2-R SEQ ID NO: 6
- 3F-F SEQ ID NO: 9
- deionized water was added to make the total amount 49.5 ⁇ 1.
- Phusion DNA Polymerase (FINNZYMES) 0.5 z 1 was added, and PCR was performed.
- the PCR reaction was performed under conditions of 30 cycles, with one cycle consisting of 98 ° C for 10 seconds, 55 ° C for 15 seconds, 72 ° C for 1 minute 30 seconds.
- the obtained PCR product was designated as PCR product no.
- PCR product no.1 and PCR product ⁇ ⁇ 2 DNA were mixed one by one.
- 10X buffer solution 10 ⁇ 1, 2mM dNTP mixture 4 ⁇ 1, 10 ⁇ primer ⁇ 2-F (SEQ ID NO: 4) attached to Phusion High-Fidelity DNA Polymerase Kit (F NZYMES) And ⁇ 2-R (SEQ ID NO: 6) were added respectively, and finally deionized water was added to make the total amount 49.5 / z 1.
- F NZYMES Phusion High-Fidelity DNA Polymerase Kit
- ⁇ 2-R SEQ ID NO: 6
- deionized water was added to make the total amount 49.5 / z 1.
- 0.5 z 1 of Phusion DNA Polymerase (FINNZYMES) was added, and PCR was performed.
- the PCR reaction was performed under the conditions of 30 cycles, with one cycle consisting of 98 ° C for 10 seconds, 55 ° C for 15 seconds, and 72 ° C for 2 minutes.
- the obtained PCR product
- J6 / JFH1 cDNA and the purified PCR product no. 5 were digested with the restriction enzyme Kpnl, and each HCV cDNA fragment was fractionated by agarose gel electrophoresis and purified. These two DNA fragments were mixed with Ligation Mix (Takara Bio Inc., Japan), and the two DNA fragments were ligated. This vector was named PJ6 / JFH-1 (1XFLAG).
- This pJ6 / JFH-1 (1XFLAG) consists of 5 ′ untranslated region, Core protein code sequence, E1 protein coding sequence, E2 protein coding sequence, p7 Protein coding sequence, sequence encoding up to N-terminal 16 amino acid residues of NS2 protein region, and sequence encoding from N-terminal 17 amino acid residues to C-terminus of NS2 protein region of JFH-1 strain, NS3 protein code Sequence, NS4A protein coding sequence, NS4B protein coding sequence, NS5A protein coding sequence, NS5B protein region and base sequence encoding a chimeric gene consisting of 3 'untranslated region, and the FLAG peptide sequence in the HVR1 region of E2 above Contains the coding base sequence.
- J6 / JFH1 cDNA and the purified PCR product no. 6 were digested with restriction enzyme Kpnl, and each HCV cDNA fragment was fractionated by agarose gel electrophoresis and purified.
- FLAG in order from 5 to 3 'side, 5' untranslated region derived from J6CF strain, Core protein coding sequence, E1 protein coding sequence, E2 protein coding sequence, p7 protein coding sequence and N NS2 protein region coding sequence up to N-terminal 16 amino acid residues, JFH-1 strain NS2 protein region coding from N-terminal 17 amino acid residues to C-terminal, NS3 protein coding sequence, NS4A A base sequence encoding a chimeric gene consisting of a protein code sequence, NS4B protein coding sequence, NS5A protein coding sequence, NS5B protein region and 3 'untranslated region, and a FLAG peptide sequence in the HVR1 region of E 2 above The base sequence is repeated three times.
- PJ6 / JFH-1 is SEQ ID NO: 10
- pJ6 / JFH-l (1XFLAG) is SEQ ID NO: 1
- pJ6 / JFH-l (3 XFLAG) is SEQ ID NO: 12
- these nucleotide sequences are shown in the Sequence Listing. .
- Example 2 In vitro RNA synthesis and introduction into cells
- PJ6 / JFH-1, pJ6 / JFH-1 (1XFLAG) and pJ6 / JFH-1 (3XFLAG) were cleaved with Xba I, extracted with phenol / form mouth form, and ethanol precipitated.
- each HCV RNA was synthesized using MEGAsci'ipt T7 kit (Ambion).
- J6 / JFH-1, J6 / JFH-1 (3XFLAG) HCV Core protein contained in the culture supernatant was quantified using the HCV antigen ELI SA test kit (Ohso) at the time of passage of each cell into which RNA was introduced. Then, the production of HCV particles was confirmed. As a result, J6 / JFH-1 RNA introduction was almost constant with no change in production. However, when J6 / JFH-1 (3XFLAG) RNA was introduced, the amount of HCV Core in the culture supernatant decreased over time until the 21st day of introduction. As a result, the core production was almost the same as that of J 6 / JFH-1 after 35 days (Fig. 3).
- J6 / JFH-1 (3XFL AG) RNA does not have high virus production ability in Huh-7 cells, but later, a compatible mutation necessary for virus production was introduced into the virus genome. It was thought to have the same ability to produce viruses as J6 / JFH-1 RNA.
- Example 4 Expression of HCV protein by J6 / JFH-1 (3XFLAG) RNA-introduced cells
- V protein expression was confirmed by Western blotting.
- Cell extract samples obtained from Huh-7 cells into which RNA was not introduced were used as negative subjects.
- Samples extracted from each cell were subjected to SDS-PAGE and blotted onto a PVDF membrane (I thigh obilon-P, Milli pore).
- anti-core monoclonal antibody anti-FLAG monoclonal antibody (M2 antibody, Sigma) and anti-E2 monoclonal antibody, and HRP-labeled secondary antibody that recognizes these antibodies, ECL Plus (GE Healthcare) Core protein and E2 protein translated in the cell were detected.
- Example 6 In order to evaluate the infectivity of the J6 / JFH-1 (3XFLAG) virus purified in Example 6, an infection experiment using cultured cells was performed. Huh-7 cells in one 8 wel l glass chamber
- the cells were seeded at 1 ⁇ 10 4 cell / wel, cultured for 24 hours, and then infected with a virus solution equivalent to 1 fmol of HCV Core for 3 hours. After infection, the cells were washed twice with DMEM (Sigma) and then cultured for 4 days. After 4 days, the total RNA in the cells was extracted according to the manual attached to Trizol Reagent (Invitrogen). The amount of HCV RNA in this total RNA was measured by quantitative RT-PCR.
- the primers and probes used are sense primer S-17 (SEQ ID NO: 1 3), antisense primer R-19 (SEQ ID NO: 14) and Taqman probe (SEQ ID NO: 1) targeting the 5'-UTR region of HCV RNA. 1 5) was used. Mix this primer and probe with the extracted total RNA, and use TaqMan EZ RT-PCR.
- RT-PCR reaction solution was prepared according to the attached manual of CORE REAGENTS (Applied Biosystems) and detected by 7500 Fast Real-Time PCR System (Applied Biosys tems). As a result, it was shown that the purified J6 / JFH-1 (3XFLAG) virus solution was infectious to Huh-7 cells (Fig. 9). From this, it can be seen that F in the HVR1 region of HCV E2
- Viruses containing the LAG tag sequence can be purified with high purity, and the purified virus was shown to be infectious.
- Example 8 Construction of J6 / JFH-1 (1XFLAG) E2 N ⁇ K and J6 / JFH-1 (3XFLAG) E2 N ⁇ K mutant plasmids
- J6 / JFH-l (1XFLAG) was used as a kit, and 10 X buffer solution 10 1 or 2 mM dNTP mixture solution attached to Phusion High-Fidelity DNA Polymerase kit (FI ⁇ ZYMES) was used. 4 ⁇ l, 10 / M primers 1141S-2a (SEQ ID NO: 16) and: [6 E2-KR (SEQ ID NO: 17) were added respectively, and deionized water was finally added to make the total amount 49.5 / z1. Thereafter, Phusion DNA Polymerase (FINNZYMES) was added in an amount of 0.5 ⁇ l and PCR was performed. The PCR reaction was performed under the conditions of 30 cycles with a cycle consisting of 98 ° C for 10 seconds, 55 ° C for 15 seconds, 72 ° C for 1 minute 30 seconds as one cycle. The obtained PCR product was designated as PCR product no.
- FI ⁇ ZYMES Phusion High-Fidelity DNA Polymerase kit
- PJ6 / JFH-1 (3XFLAG) was used as a saddle, 10X buffer solution 10 / _tl, 2mM dNTP mixture solution 4 ⁇ 1, attached to Phusion High-Fidelity DNA Polyraase kit (FINNZYMES), 10 ⁇ L of primer 1141S-2a (SEQ ID NO: 16) and J6E2-K-R (SEQ ID NO: 17) were each added to 1 1 each, and finally deionized water was added to make the total amount 49.5 ⁇ 1. Thereafter, Phusion DNA Polymerase (FINNZYMES) was added at 0.5 ⁇ x / x 1 and PCR was performed. The PCR reaction was performed under the conditions of 30 cycles, with one cycle consisting of 98 ° C for 10 seconds, 55 ° C for 15 seconds, 72 ° C for 1 minute 30 seconds. The obtained PCR product was designated as PCR product no.
- PCR reaction was performed.
- the PCR reaction was performed under the conditions of 30 cycles, with one cycle consisting of 98 ° C for 10 seconds, 55 ° C for 15 seconds, and 72 ° C for 2 minutes.
- the obtained PCR product was designated as PCR product no.
- the PCR reaction was performed under the conditions of 30 cycles, with one cycle consisting of 98 ° C for 10 seconds, 55 ° C for 15 seconds, and 72 ° C for 2 minutes.
- the obtained PCR product was designated as PCR product no.
- Each PCR product was purified and dissolved in 0 of 301.
- the NA fragment was fractionated by agarose gel electrophoresis and purified. These two DNA fragments were mixed with Ligation Mix (Takara Bio Inc., Japan), and the two DNA fragments were ligated. This vector was named PJ6 / JFH-1 (1XFLAG) N ⁇ K. This pJ6 / JFH-1 (1XFLAG)
- N ⁇ K in order from 5 to 3 ′, 5 ′ untranslated region from the J6CF strain, Core protein coding sequence, E1 protein coding sequence, E2 protein coding sequence, p7 protein coding sequence
- the sequence encoding up to 16 amino acid residues at the N-terminal of the NS2 protein region, and the N-terminal 17 amino acid residue of the NS2 protein region of JFH-1 strain The base encoding the chimeric gene consisting of C-terminal coding sequence, NS3 protein coding sequence, NS4A protein coding sequence, NS4B protein coding sequence, NS5A protein coding sequence, NS5B protein region and 3 'untranslated region
- the NS2 HVR1 region contains the nucleotide sequence encoding the FLAG peptide sequence, and the N-terminal sequence of the Core protein is counted as 1, so that the 532nd amino acid becomes lysine. Including the base sequence.
- PJ6 / JFH1 and the purified PCR product no. 11 were digested with the restriction enzyme Kpnl, and each HCV cDNA fragment was fractionated by agarose gel electrophoresis and purified. These two DNA fragments were mixed with Ligation Mix (Takara Bio Inc., Japan), and the two DNA fragments were ligated.
- This vector was named PJ6 / JFH-1 (3XFLAG) N ⁇ K.
- This pJ6 / JFH-1 (3XFLAG) N ⁇ K is in order from 5 'side to 3' side, 5 'untranslated region from J6CF strain, Cole protein coding sequence, E1 protein coding sequence, E2 protein coding sequence , P7 protein coding sequence and NS2 protein region coding sequence up to N-terminal 16 amino acid residues, and JFH-1 strain NS2 protein region N-terminal 17 amino acid residue to C-terminal coding sequence, NS3 protein NS3A protein coding sequence, NS4B protein coding sequence, NS5A protein coding sequence, NS5 B protein region and 3 'non-translated region. It contains a nucleotide sequence that repeats the peptide sequence three times, and counts as 1 for methionine, the N-terminal sequence of the Core protein. Including so that base sequence.
- PJ6 / JFH-1 (1XFLAG) N ⁇ K is SEQ ID NO: 20 and pJ6 / JFH-1 (3XFLAG) N ⁇ K is SEQ ID NO: 21. These nucleotide sequences are shown in the Sequence Listing.
- Example 9 Preparation of J6 / JFH-1 (1XFLAG) E2 N ⁇ K and J6 / JFH-1 (3XFLAG) E2 N ⁇ K virus
- Each of the plasmids prepared in Example 8 was cut with Xbal, extracted with phenol chloroform, and precipitated with ethanol.
- Each of the HCV RNAs was synthesized using MEGAscript T7 kit (Ambion) using the cleaved plasmid as a cage.
- HCV antigen ELISA test kit Ohso
- J6 / JFH-1 (1XFLAG) E2 N ⁇ K and J6 / JFH-1 (3XFLAG) E2 N ⁇ K RNA HCV Core protein contained in the supernatant was quantified to confirm the production of HCV particles. Comparison of the amount of HCV Core contained in the culture supernatant of cells introduced with RNA without introduction of mutations and the amount of HCV Core contained in the culture supernatant of cells introduced with mutations from early to late stage of culture It was shown that the latter was higher.
- Example 10 Construction of JFH-1 plasmid with FLAG tag sequence inserted into HCV E2 HVR1 region
- genotype 2a strain JFH-1 strain (GenBank accession number AB047639, Kato, An epitope tag sequence was introduced into HVR1 of T. et al., Gastroenterology, 125 (2003) pl808-1817).
- epitope tag cDNA with the FLAG sequence repeated once or three times was inserted.
- JFH-1 (1XFLAG) and JFH-1 (3XFLAG) are called JFH-1 (1XFLAG) and JFH-1 (3XFLAG), respectively.
- the N-terminal sequence of the E2 protein encoded by pJFH-1 (sometimes called pJFHl) is SEQ ID NO: 2 2, and the N-terminal sequence of the E2 protein encoded by pJFH-1 (1XFLAG) is SEQ ID NO: 23.
- the N-terminal sequence of the E2 protein encoded by pJFH-1 (3XFLAG) is shown in SEQ ID NO: 24.
- Figures 12 (A) to 12 (C) show how to make these plasmids.
- JFH-1 c ⁇ as a kit, 10 ⁇ l of 10 ⁇ l buffer solution and 2 mM dNTP mixture supplied with Phusion High-Fidelity DNA Polymerase Kit (FI ⁇ ZYMES) were used. 4 / l, 10 ⁇ primers JF-F (SEQ ID NO: 2 5) and JFH1- IF-R
- PCR product (SEQ ID NO: 26) was added to each ⁇ , and finally deionized water was added to make the total amount 49.5 ⁇ 49. Then add Phusion DNA Polymerase (FI ⁇ ZYMES) 0 ⁇ 5 ⁇ 1 Then, a PCR reaction was performed. The PCR reaction was performed under the conditions of 30 cycles, with one cycle consisting of 98 ° C for 10 seconds, 55 ° C for 15 seconds, and 72 ° C for 30 seconds. The obtained PCR product was designated as PCR product No. 12.
- PCR reaction is 98 ° C for 10 seconds, 55 ° C for 15 seconds, 72. C The process consisting of 1 minute and 30 seconds was taken as one cycle, and was performed under the conditions of 30 cycles. The obtained PCR product was designated as PCR product no.
- PCR product was purified and dissolved in 0 of 151.
- the PCR product no. 12 and PCR products ⁇ ⁇ 1 3 of DNA were mixed in each ⁇ ⁇ ⁇ .
- This is a saddle type, Phusion High-Fi Delivery DNA Polymerase kit (FINNZYMES) supplied with 10 X buffer 10 1, 2 mM dNTP mixture 4 ⁇ 1, 10 ⁇ ⁇ ⁇ ⁇ ⁇ primers JFH1- F (SEQ ID NO: 2 5) and 3189R-IH (SEQ ID NO: 19) was added in an amount of 1 ⁇ 1 each, and deionized water was finally added to make the total amount 49.5 ⁇ 1.
- Phusion DNA Polymerase (FINNZYMES) was added for 0.5 ⁇ 1 ⁇ l and PCR reaction was performed.
- the PCR reaction was performed under the conditions of 30 cycles, with one cycle consisting of 98 ° C for 10 seconds, 55 ° C for 15 seconds, and 72 ° C for 2 minutes.
- the obtained PCR product was designated as PCR product ⁇ ⁇ 16.
- the PCR reaction was performed under the conditions of 30 cycles, with one cycle consisting of 98 ° C for 10 seconds, 55 ° C for 15 seconds, and 72 ° C for 2 minutes.
- the obtained PCR product was designated as PCR product no.
- Each PCR product was purified and dissolved in 0 of 301.
- pJFH-1 cDNA and purified PCR product no. 16 were deleted with restriction enzymes EcoRI and Kpnl, and each HCV cDNA fragment was fractionated by agarose gel electrophoresis and purified. These two DNA fragments were mixed with Ligation Mix (Takara Bio Inc., Japan), and the two DNA fragments were ligated.
- This vector was named pJFH-1 (1XFLAG).
- This pJFH-1 (IX FLAG) is a nucleotide sequence that codes for the gene of the JFH1 strain, and includes a nucleotide sequence that encodes the FLAG peptide sequence in the HVR1 region of E2.
- This vector was named pj FH-1 ( 3 XFLAG).
- This pJFH-1 C3XFLAG) is a base sequence encoding the gene of JTH1, and contains a base sequence in which the FLAG peptide sequence is repeated three times in the HVR1 region of E2.
- a TH1 strain with a genotype lb from 5 ′ UTR to the N-terminal 16 amino acid residue of NS2 ((Wakita, T. et al., J. Biol. Chem., 269, 14205-1 4210, 1994, JP-A-2004-179), NS2 N-terminal 17 amino acid residues to 3 'UTR genotype 2a strain JFH-1 (GenBank accession number AB047639, Kato, T.
- TH / JFH-1 chimera cDNA was used to introduce an epitope tag sequence into HVR1 of TH / JFH1.
- These plasmids were inserted pTH / JFH-1 (1XFLAG) and pTH / JFH-1 (3XFLAG), respectively, near the insertion site of the FLAG tag translated from these genes.
- This amino acid sequence is shown in FIG. 13 as being derived from the N-terminal amino acid sequence of the E 2 protein.
- the N-terminal sequence of the E2 protein encoded by ⁇ / JFH-l is SEQ ID NO: 3 2
- the N-terminal sequence of the E2 protein encoded by pTH / JF H-1 (1XFLAG) is SEQ ID NO: 3 3
- pTH / JFH- The N-terminal sequence of E2 protein encoded by 1 (3XFLAG) is shown in SEQ ID NO: 34.
- Figure 14 shows how these plasmids are produced.
- TH / JFH-1 was prepared. Using pJFH-1 cDNA as a saddle, add 10 ⁇ l of 10 X buffer and 4 ⁇ l, 10 ⁇ m of 2 mM dNTP mix attached to Phusion High-Fidelity DNA Polymerase kit (FINNZYMES). Primer JFm- ⁇ (SEQ ID NO: 4 3) and JFH1-B (SEQ ID NO: 4 4) were added in an amount of ⁇ ⁇ respectively, and deionized water was finally added to make the total amount 49.5 ⁇ 1.
- PCR reaction was performed to amplify the 5 ′ untranslated region of JFH-1 and a part of the TH core contained in primer JFH1-B.
- the PCR reaction was performed under the conditions of 30 cycles, with one cycle consisting of 98 ° C for 10 seconds, 55 ° C for 15 seconds, and 72 ° C for 30 seconds.
- the obtained PCR product was designated as PCR product no.
- PCR reaction performs a part of NS2 from the TH core and part of the 5 'untranslated region of JFH-1 contained in ply TH-C.
- a part of NS2 of JFH-1 contained in the rimer YH-D was amplified.
- the PCR reaction was performed under the conditions of 30 cycles, with one cycle consisting of 98 ° C for 10 seconds, 55 ° C for 15 seconds, and 72 ° C for 30 seconds.
- the obtained PCR product was designated as PCR product no.
- pJFH-1 was used as a saddle, and 10X buffer was added to the Phusion High-Fidelity DNA Polymerase kit (FINNZ YMES).
- 10 1 2raM dNTP mixture was added to 10 M ply JFm-E (SEQ ID NO: 47) and JFH1-F (SEQ ID NO: 48) was added in an amount of ⁇ , and finally deionized water was added to make the total amount 49.5 ⁇ 1.
- Phusion DNA Polymerase (FINNZYMES) 0 ⁇ 5 ⁇ 1 and perform PCR reaction. Amplify part of NS2 NS3 of JFH-1 and part of NS2 of TH contained in ply JF-E. Went.
- the PCR reaction was performed under the conditions of 30 cycles, with one cycle consisting of 98 ° C for 10 seconds, 55 ° C for 15 seconds, and 72 ° C for 30 seconds. What is the PCR product obtained? 13 ⁇ 4 product ⁇ ). 20.
- FIG. 14 (A) (C) A method for producing pTH / JFH-1 (1XFLAG) pTH / JFH-1 (3XFLAG) using this plasmid is shown in FIG. 14 (A) (C). Specifically, the 10X buffer solution 10 ⁇ 1 2m dNT that was attached to the Phusion High-Fidelity DNA Polymerase Kit (FIYZYMES) using the pTH / JFH-1 cDNA as a saddle type was used.
- FIYZYMES Phusion High-Fidelity DNA Polymerase Kit
- PCR product no 4 1 10 liters of ply TH-F (SEQ ID NO: 3 5) and TH-1F-R (SEQ ID NO: 36) were added in an amount of ⁇ ⁇ ⁇ ⁇ ⁇ respectively, and finally deionized water was added to make the total amount 49.5 ⁇ 1. Then, add 0.5 ⁇ 1 of Phusion DNA Polymerase (FINNZYMES) and use PCR. Reaction was performed. The PCR reaction was performed under the conditions of 30 cycles, with one cycle consisting of 98 ° C for 10 seconds, 55 ° C for 15 seconds, and 72 ° C for 30 seconds. The obtained PCR product was designated as PCR product no.
- PCR reaction was carried out using Phusion DNA Polymerase (FINNZYMES) for 0.5 ⁇ 5/1 force. The PCR reaction was performed under conditions of 30 cycles, with one cycle consisting of 98 ° C for 10 seconds, 55 ° C for 15 seconds, 72 ° C for 1 minute 30 seconds. The obtained PCR product was designated as PCR product no.23.
- PCR product was designated as PCR product no.24.
- PCR product was designated as PCR product no.25.
- PCR product no. 24 and PCR product no. 25 ⁇ A were mixed one by one.
- 10X buffer solution supplied with Phusion High-Fidelity DNA Polymerase kit (FINNZYMES), lO w 1, 2mM dNTP mixture 4 1, 10 / _t M Primer TH- F (SEQ ID NO: 3 5) and 3189R-IH (SEQ ID NO: 19) were added respectively, and deionized water was finally added to make the total amount 49.5 ⁇ 1. Thereafter, 0.5 ⁇ l of Phusion DNA Polymerase (FINNZYMES) was added and PCR was performed.
- the PCR reaction was performed under the conditions of 30 cycles, with one cycle consisting of 98 ° C for 10 seconds, 55 ° C for 15 seconds, and 72 ° C for 2 minutes.
- the obtained PCR product was designated as PCR product no.
- Each PCR product was purified and dissolved in 30 ⁇ 1 3 ⁇ 40.
- pTH / JFH-1 cDNA and the purified PCR product no. 26 were digested with the restriction enzyme Kpnl, and each HCV cDNA fragment was fractionated by agarose gel electrophoresis and purified. These two DNA fragments were mixed with Ligation Mix (Takara Bio Inc., Japan), and the two DNA fragments were linked.
- This vector was named pTH / JFH-1 (1XFLAG).
- This pTH / JFH-1 (1XFL AG) is a base sequence encoding a gene of TH1 strain, and includes a base sequence encoding a FLAG peptide sequence in the HVR1 region of E2.
- pTH / JFHl cDNA and the purified PCR product no. 27 were digested with the restriction enzyme Kpnl, and each HCV cDNA fragment was fractionated by fuzzy mouth gel electrophoresis and purified. These two DNA fragments were mixed with Ligation Mix (Takara Bio Inc., Japan), and the two DNA fragments were ligated.
- This vector was named pTH / JFH-1 (3XFLAG). This pTH / JFH-1
- (3XFLAG) is a base sequence encoding a gene of ⁇ 1 strain, and includes a base sequence obtained by repeating the FLAG peptide sequence three times in the HVR1 region of E2.
- pTH / JFHl is SEQ ID NO: 40
- pTH / JFH-1 (1XFLAG) is SEQ ID NO: 41
- pTH / JFH-1 (3 XFLAG) is SEQ ID NO: 42
- these nucleotide sequences are shown in the Sequence Listing.
- the epitope-tagged HCV particle-containing culture supernatant is passed through a column packed with a carrier to which an anti-epitope-tagged antibody is immobilized, whereby the epitope-tagged HCV particle is specifically adsorbed, and then the HCV particle is eluted.
- a column packed with a carrier to which an anti-epitope-tagged antibody is immobilized whereby the epitope-tagged HCV particle is specifically adsorbed, and then the HCV particle is eluted.
- the HCV particle is eluted.
- HCV particles in a method for producing and purifying HCV particles in a cultured cell system, HCV particles can be purified more easily and with a higher purity than conventional methods. Since the HCV particles provided by the method of the present invention have high purity, they are suitable as vaccines for preventing or treating HCV. Furthermore, the epotope-tagged HCV particles of the present invention can be used as a tool for inducing antibodies against HCV.
- the HCV particles provided by the method of the present invention have a high purity, they can be suitably used as a vaccine for preventing or treating HCV. Furthermore, the epitope-tagged HCV particles according to the present invention can be used as a tool for inducing antibodies against HCV. All publications, patents and patent applications cited herein are incorporated herein by reference in their entirety. Sequence table free text
- SEQ ID NO: 2 N-terminal sequence of E2 protein encoding pJ6 / JFH-l (lXFLAG)
- SEQ ID NO: 3 N-terminal sequence of E2 protein encoding pJ6 / JFH-l (3XFLAG)
- SEQ ID NO: 4 Primer-(E2-F)
- Sequence number 8 Primer-(E2-F) Sequence number 9: Primer (3F-R)
- SEQ ID NO: 14 Primer (R-19)
- SEQ ID NO: 17 Primer (J6E2-K-R)
- SEQ ID NO: 18 Primer (J6E2-K-F)
- SEQ ID NO: 22 N-terminal sequence of E2 protein encoded by pJFH-1
- SEQ ID NO: 2 3 N-terminal sequence of E2 protein encoded by pJFH-1 (1XFLAG)
- SEQ ID NO: 2 4 N-terminal sequence of E2 protein encoded by pJFH-1 (3XFLAG)
- SEQ ID NO: 2 5 Primer (JFH1 -F)
- SEQ ID NO: 2 6 Primer (Ji3 ⁇ 4 ⁇ 1F-R)
- SEQ ID NO: 2 7 Primer (JF1H-1F-F)
- SEQ ID NO: 2 8 Primer (JFH1-3F-R)
- SEQ ID NO: 29 Primer (JFH1-3F-F)
- SEQ ID NO: 30 pJFH-1 (1XFLAG)
- SEQ ID NO: 3 2 N-terminal sequence of E2 protein encoded by pTH / JFHl
- SEQ ID NO: 3 3 N-terminal sequence of E 2 protein encoded by pTH / JFH-1 (1XFLAG)
- SEQ ID NO: 3 4 pTH / JFH -1 (3XFLAG) encoded E2 protein N-terminal sequence
- SEQ ID NO: 35 Primer (TH-F)
- SEQ ID NO: 3 6 Primer (TH-1F-R)
- SEQ ID NO: 3 7 Primer (TH-1F-F)
- SEQ ID NO: 3 8 Primer (TH-3F-R)
- SEQ ID NO: 3 9 Primer (TH-3F-F)
- SEQ ID NO: 40 pTH / JFHl
- SEQ ID NO: 4 3 Primer (JFH1-A)
- SEQ ID NO: 4 4 Primer (JFH1-B)
- SEQ ID NO: 45 Primer (TH-C)
- SEQ ID NO: 47 Primer (JFHl-E)
- SEQ ID NO: 48 Primer (JFHl-F)
- SEQ ID NO: 4 9 Epitope tag peptide (1XFLAG + L inker)
- SEQ ID NO: 50 Epitope tag peptide (3XFLAG + Linker)
- SEQ ID NO: 5 1 Epitope tag peptide (1XFLAG)
- SEQ ID NO: 5 2 Epitope tag peptide (3XFLAG) sequence Number 5 3: Linker
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200880108160A CN101835896A (zh) | 2007-07-13 | 2008-07-11 | 表位标记的丙型肝炎病毒颗粒的制备和应用 |
CA2696437A CA2696437A1 (en) | 2007-07-13 | 2008-07-11 | Production and use of epitope-tagged hepatitis c virus particle |
US12/668,861 US20100278865A1 (en) | 2007-07-13 | 2008-07-11 | Production and use of epitope-tagged hepatitis c virus particle |
JP2009523678A JP5657251B2 (ja) | 2007-07-13 | 2008-07-11 | エピトープタグ化c型肝炎ウイルス粒子の作製と利用 |
EP08778269A EP2186893A4 (en) | 2007-07-13 | 2008-07-11 | PREPARATION AND USE OF A EPITOPEAGED HEPATITIS C VIRUS PARTICLE |
AU2008276880A AU2008276880B2 (en) | 2007-07-13 | 2008-07-11 | Production and use of epitope-tagged hepatitis C virus particle |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007184587 | 2007-07-13 | ||
JP2007-184587 | 2007-07-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009011413A1 true WO2009011413A1 (ja) | 2009-01-22 |
Family
ID=40259739
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2008/062977 WO2009011413A1 (ja) | 2007-07-13 | 2008-07-11 | エピトープタグ化c型肝炎ウイルス粒子の作製と利用 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20100278865A1 (ja) |
EP (1) | EP2186893A4 (ja) |
JP (1) | JP5657251B2 (ja) |
CN (1) | CN101835896A (ja) |
AU (1) | AU2008276880B2 (ja) |
CA (1) | CA2696437A1 (ja) |
WO (1) | WO2009011413A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010022727A1 (en) * | 2008-08-28 | 2010-03-04 | Hvidovre Hospital | INFECTIOUS GENOTYPE 1a, 1b, 2a, 2b, 3a, 5a, 6a and 7a HEPATITIS C VIRUS LACKING THE HYPERVARIABLE REGION 1 (HVR1) |
WO2014051111A1 (ja) * | 2012-09-28 | 2014-04-03 | 国立大学法人 神戸大学 | C型肝炎ウイルス粒子形成促進剤及びc型肝炎ウイルス粒子の産生方法 |
CN103740656A (zh) * | 2014-01-22 | 2014-04-23 | 大连汉信生物制药有限公司 | 重组汉逊酵母戊型肝炎类病毒颗粒的纯化方法及应用 |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8618275B2 (en) * | 2007-05-18 | 2013-12-31 | Hvidovre Hospital | Efficient cell culture system for hepatitis C virus genotype 5A |
US8569472B2 (en) * | 2007-12-20 | 2013-10-29 | Hvidovre Hospital | Efficient cell culture system for hepatitis C virus genotype 6A |
WO2010017818A1 (en) | 2008-08-15 | 2010-02-18 | Hvidovre Hospital | Efficient cell culture system for hepatitis c virus genotype 2b |
US8506969B2 (en) | 2008-08-15 | 2013-08-13 | Hvidovre Hospital | Efficient cell culture system for hepatitis C virus genotype 7a |
WO2010037403A1 (en) | 2008-10-03 | 2010-04-08 | Hvidovre Hospital | Hepatitis c virus expressing reporter tagged ns5a protein |
CN103360476B (zh) * | 2011-03-10 | 2014-10-01 | 中国人民解放军第二军医大学 | 经修饰的2a型丙型肝炎病毒包膜E2蛋白及其应用 |
CN103360474B (zh) * | 2011-03-10 | 2015-01-14 | 中国人民解放军第二军医大学 | 经修饰的3a型丙型肝炎病毒包膜E2蛋白及其应用 |
CN103360473B (zh) * | 2011-03-10 | 2015-01-14 | 中国人民解放军第二军医大学 | 经修饰的6型丙型肝炎病毒包膜e2蛋白及其应用 |
CN103360477B (zh) * | 2011-03-10 | 2015-01-14 | 中国人民解放军第二军医大学 | 经修饰的4型丙型肝炎病毒包膜e2蛋白及其应用 |
CN103360475B (zh) * | 2011-03-10 | 2015-01-14 | 中国人民解放军第二军医大学 | 经修饰的5型丙型肝炎病毒包膜e2蛋白及其应用 |
WO2016174227A1 (en) * | 2015-04-30 | 2016-11-03 | Curevac Ag | Method for in vitro transcription using an immobilized restriction enzyme |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004000179A (ja) | 2002-03-29 | 2004-01-08 | Toray Ind Inc | C型慢性肝炎、肝硬変、肝癌病態を呈するモデル動物及びその作製方法 |
WO2004104198A1 (ja) | 2003-05-26 | 2004-12-02 | Toray Industries, Inc. | 遺伝子型2aのC型肝炎ウイルス(HCV)ゲノム由来の核酸を含む核酸構築物、及び該核酸構築物を導入した細胞 |
WO2005080575A1 (ja) | 2004-02-20 | 2005-09-01 | Tokyo Metropolitan Organization For Medical Research | ヒトc型肝炎ウイルスの全長ゲノムを含む核酸構築物及び該核酸構築物を導入した組換え全長ウイルスゲノム複製細胞、並びにc型肝炎ウイルス粒子の作製方法 |
WO2006022422A1 (ja) | 2004-08-24 | 2006-03-02 | Tokyo Metropolitan Organization For Medical Research | 自律複製能を有する改変されたヒトc型肝炎ウイルスゲノムrna |
WO2007037428A1 (ja) | 2005-09-30 | 2007-04-05 | Japan As Represented By Director-General Of National Institute Of Infectious Diseases | 感染性c型肝炎ウイルス粒子高産生系 |
JP2007184587A (ja) | 2005-12-30 | 2007-07-19 | Agere Systems Inc | 複数の半導体光デバイスおよび能動冷却デバイスからなる光学アセンブリ |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003279240A1 (en) * | 2002-06-21 | 2004-01-06 | Genetix Pharmaceuticals, Inc. | Methods for purifying viral particles for gene therapy |
WO2006096459A2 (en) * | 2005-03-04 | 2006-09-14 | The Rockefeller University | Infectious, chimeric hepatitis c virus, methods of producing the same and methods of use thereof |
-
2008
- 2008-07-11 CN CN200880108160A patent/CN101835896A/zh active Pending
- 2008-07-11 WO PCT/JP2008/062977 patent/WO2009011413A1/ja active Application Filing
- 2008-07-11 JP JP2009523678A patent/JP5657251B2/ja not_active Expired - Fee Related
- 2008-07-11 US US12/668,861 patent/US20100278865A1/en not_active Abandoned
- 2008-07-11 CA CA2696437A patent/CA2696437A1/en not_active Abandoned
- 2008-07-11 EP EP08778269A patent/EP2186893A4/en not_active Withdrawn
- 2008-07-11 AU AU2008276880A patent/AU2008276880B2/en not_active Ceased
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004000179A (ja) | 2002-03-29 | 2004-01-08 | Toray Ind Inc | C型慢性肝炎、肝硬変、肝癌病態を呈するモデル動物及びその作製方法 |
WO2004104198A1 (ja) | 2003-05-26 | 2004-12-02 | Toray Industries, Inc. | 遺伝子型2aのC型肝炎ウイルス(HCV)ゲノム由来の核酸を含む核酸構築物、及び該核酸構築物を導入した細胞 |
WO2005080575A1 (ja) | 2004-02-20 | 2005-09-01 | Tokyo Metropolitan Organization For Medical Research | ヒトc型肝炎ウイルスの全長ゲノムを含む核酸構築物及び該核酸構築物を導入した組換え全長ウイルスゲノム複製細胞、並びにc型肝炎ウイルス粒子の作製方法 |
WO2006022422A1 (ja) | 2004-08-24 | 2006-03-02 | Tokyo Metropolitan Organization For Medical Research | 自律複製能を有する改変されたヒトc型肝炎ウイルスゲノムrna |
WO2007037428A1 (ja) | 2005-09-30 | 2007-04-05 | Japan As Represented By Director-General Of National Institute Of Infectious Diseases | 感染性c型肝炎ウイルス粒子高産生系 |
JP2007184587A (ja) | 2005-12-30 | 2007-07-19 | Agere Systems Inc | 複数の半導体光デバイスおよび能動冷却デバイスからなる光学アセンブリ |
Non-Patent Citations (26)
Title |
---|
"Antibodies: A Laboratory Manual", 1988 |
"Antibodies: A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY |
"Remington's Pharmaceutical Science", MARK PUBLISHING COMPANY |
APPAIAHGARI ET AL., VACCINE, vol. 22, 2004, pages 3669 - 3675 |
CHOO, QL. ET AL., SCIENCE, vol. 244, 1989, pages 359 - 362 |
EJIMA, D. ET AL., ANAL. BIOCHEM., vol. 345, 2005, pages 250 - 257 |
HIJIKATA, M. ET AL., BIOCHEM BIOPHYS RES COMMUN., vol. 175, 1991, pages 220 - 228 |
KATO, T. ET AL., GASTROENTEROLOGY, vol. 125, 2003, pages 1808 - 1817 |
LINDENBACH B.D. ET AL.: "Complete replication of hepatitis C virus in cell culture", SCIENCE, vol. 309, 2005, pages 623 - 626, XP002993377 * |
LINDENBACH, BD. ET AL., SCIENCE, vol. 309, 2005, pages 623 - 626 |
LOHMANN, V. ET AL., J. VIROL., vol. 75, 2001, pages 1437 - 1449 |
MORADPOUR ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 246, 1998, pages 920 - 924 |
NEUMANN, G. ET AL., VIROLOGY, vol. 202, 1994, pages 477 - 479 |
OP DE BEECK, A. ET AL., J. GEN. VIROL., vol. 82, 2001, pages 2589 - 2595 |
PUNTORIERO, G. ET AL., EMBO J., vol. 17, 1998, pages 3521 - 3533 |
SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", vol. 3, 2001 |
See also references of EP2186893A4 * |
TAKAHASHI H. ET AL.: "Epitope Tag o Fuka shita Kumikae HCV Ryushi no Sakusei to Seijo Kaiseki", DAI 55 KAI THE JAPANESE SOCIETY OF VIROLOGY GAKUJUTSU SHUKAI PROGRAM . SHOROKUSHU, 1 October 2007 (2007-10-01), pages 368 * |
VOISSET, C.; DUBUISSON, BIOLOGY OF THE CELL, vol. 96, 2004, pages 413 - 420 |
WAKITA T. ET AL.: "Production of infectious hepatitis C virus in tissue culture from a cloned viral genome", NAT. MED., vol. 11, 2005, pages 791 - 796, XP002993378 * |
WAKITA, T. ET AL., J. BIOL. CHEM., vol. 269, 1994, pages 14205 - 14210 |
WAKITA, T. ET AL., NAT. MED., vol. 11, 2005, pages 791 - 796 |
YANAGI M. ET AL.: "Hepatitis C virus: an infectious molecular clone of a second major genotype (2a) and lack of viability of intertypic 1 and 2a chimeras", VIROLOGY, vol. 262, 1999, pages 250 - 263, XP000911930 * |
YANAGI, M. ET AL., VIROLOGY, vol. 262, 1999, pages 250 - 263 |
ZAHN, A.; ALLAINL, J.P., J. GEN. VIROL., vol. 86, 2005, pages 677 - 685 |
ZHAN A. ET AL.: "Hepatitis C virus and hepatitis B virus bind to heparin: purification of largely IgG-free virions from infected plasma by heparin chromatography", JOURNAL OF GENERAL VIROLOGY, vol. 86, 2005, pages 677 - 685, XP002491382 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010022727A1 (en) * | 2008-08-28 | 2010-03-04 | Hvidovre Hospital | INFECTIOUS GENOTYPE 1a, 1b, 2a, 2b, 3a, 5a, 6a and 7a HEPATITIS C VIRUS LACKING THE HYPERVARIABLE REGION 1 (HVR1) |
WO2014051111A1 (ja) * | 2012-09-28 | 2014-04-03 | 国立大学法人 神戸大学 | C型肝炎ウイルス粒子形成促進剤及びc型肝炎ウイルス粒子の産生方法 |
JPWO2014051111A1 (ja) * | 2012-09-28 | 2016-08-25 | 国立大学法人神戸大学 | C型肝炎ウイルス粒子形成促進剤及びc型肝炎ウイルス粒子の産生方法 |
CN103740656A (zh) * | 2014-01-22 | 2014-04-23 | 大连汉信生物制药有限公司 | 重组汉逊酵母戊型肝炎类病毒颗粒的纯化方法及应用 |
Also Published As
Publication number | Publication date |
---|---|
CN101835896A (zh) | 2010-09-15 |
AU2008276880A1 (en) | 2009-01-22 |
US20100278865A1 (en) | 2010-11-04 |
EP2186893A4 (en) | 2010-10-20 |
EP2186893A1 (en) | 2010-05-19 |
AU2008276880B2 (en) | 2014-02-27 |
JPWO2009011413A1 (ja) | 2010-09-24 |
JP5657251B2 (ja) | 2015-01-21 |
CA2696437A1 (en) | 2009-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5657251B2 (ja) | エピトープタグ化c型肝炎ウイルス粒子の作製と利用 | |
Tanaka et al. | Hallmarks of hepatitis C virus in equine hepacivirus | |
Dimitrova et al. | Protein-protein interactions between hepatitis C virus nonstructural proteins | |
US8618275B2 (en) | Efficient cell culture system for hepatitis C virus genotype 5A | |
US8569472B2 (en) | Efficient cell culture system for hepatitis C virus genotype 6A | |
US8454974B2 (en) | Adaptive mutations allow establishment of JFH1-based cell culture systems for hepatitis C virus genotype 4A | |
US8563706B2 (en) | Efficient cell culture system for hepatitis C virus genotype 1A and 1B | |
US8506969B2 (en) | Efficient cell culture system for hepatitis C virus genotype 7a | |
US8663653B2 (en) | Efficient cell culture system for hepatitis C virus genotype 2B | |
WO2005080575A1 (ja) | ヒトc型肝炎ウイルスの全長ゲノムを含む核酸構築物及び該核酸構築物を導入した組換え全長ウイルスゲノム複製細胞、並びにc型肝炎ウイルス粒子の作製方法 | |
US8846891B2 (en) | Infectious genotype 1a, 1b, 2a, 2b, 3a, 5a, 6a and 7a hepatitis C virus lacking the hypervariable region 1 (HVR1) | |
JP5593220B2 (ja) | C型肝炎ウイルス由来のキメラ遺伝子を含む核酸 | |
US9057048B2 (en) | Infectious hepatitis C virus—high producing HCV variants and use thereof | |
US9388389B2 (en) | JFH-1 based HCV cell culture systems for NS5A of genotypes 1-7 | |
AU2012302666B2 (en) | Nucleic acid construct including nucleic acid derived from genotype 3a HCV genome | |
Rychłowska et al. | Hepatitis C-new developments in the studies of the viral life cycle | |
WO2012133735A1 (ja) | 遺伝子型1bのC型肝炎ウイルスゲノム由来の核酸を含む核酸構築物、及び該核酸構築物が導入されたC型肝炎ウイルスゲノム複製細胞、並びに感染性C型肝炎ウイルス粒子の製造方法 | |
Patel | An Investigation of the Complexes Formed Between the Hepatitis C Virus E1 and E2 Glycoproteins | |
Oniangue-Ndza | Development and characterization of subgenomic and full-length genome replicons based on the sequence of HCV AD78 strain | |
Aligo | Defining the role of the nonstructural protein 4B C-terminal domain in Hepatitis C Virus replication | |
Dhillon | Investigating virus entry using cell-culture adapted hepatitis C virus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880108160.0 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08778269 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2009523678 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2696437 Country of ref document: CA Ref document number: 12668861 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008276880 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008778269 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2008276880 Country of ref document: AU Date of ref document: 20080711 Kind code of ref document: A |